SC-435

SC-435 is an orally effective apical sodium codependent bile acid transporter (ASBT) inhibitor. SC-435 effectively removes neurotoxic bile acids and ammonia from the blood by inhibiting intestinal ASBT, thereby alleviating liver and brain damage caused by liver failure. SC-435 can alter hepatic cholesterol metabolism and lower plasma low-density lipoprotein-cholesterol concentrations[1] [2] [3].

Product Specifications

CAS Number

289037-67-8

UNSPSC

12352005

Target

Apical Sodium-Dependent Bile Acid Transporter

Type

Reference compound

Related Pathways

Membrane Transporter/Ion Channel

Applications

Metabolism-protein/nucleotide metabolism

Field of Research

Metabolic Disease

Assay Protocol

https://www.medchemexpress.com/sc-435.html

Purity

99.14

Solubility

DMSO : ≥ 50 mg/mL

Smiles

CS(=O)([O-])=O.O[C@@H]1[C@@](C2=CC=C(C=C2)OCCCC[N+]34CCN(CC4)CC3)([H])C5=CC(N(C)C)=CC=C5S(=O)(CC1(CCCC)CCCC)=O

Molecular Formula

C37H59N3O7S2

Molecular Weight

722.01

References & Citations

[1]West KL, et, al. 1-[4-[4[ (4R,5R) -3,3-Dibutyl-7- (dimethylamino) -2,3,4,5-tetrahydro-4-hydroxy-1,1-dioxido-1-benzothiepin-5-yl]phenoxy]butyl]-4-aza-1-azoniabicyclo[2.2.2]octane methanesulfonate (SC-435), an ileal apical sodium-codependent bile acid transporter inhibitor alters hepatic cholesterol metabolism and lowers plasma low-density lipoprotein-cholesterol concentrations in guinea pigs. J Pharmacol Exp Ther. 2002 Oct;303 (1) :293-9.|[2]Xie G, et al. Dysregulated bile acid signaling contributes to the neurological impairment in murine models of acute and chronic liver failure. EBioMedicine. 2018 Nov;37:294-306.|[3]West KL, et al. SC-435, an ileal apical sodium-codependent bile acid transporter inhibitor alters mRNA levels and enzyme activities of selected genes involved in hepatic cholesterol and lipoprotein metabolism in guinea pigs. J Nutr Biochem. 2005 Dec;16 (12) :722-8.